Drug side effects: an open source tool to predict adverse reactions
Researchers who developed a machine learning algorithm to predict the adverse effects of new drug compounds have released it as an open source tool.
List view / Grid view
Articles
Prophylactics for COVID-19 – known and unknown
This article outlines the ideal scientific research that should be conducted to design a prophylactic to combat COVID-19.
The hope of rejuvenation: using plasma to reverse ageing in mice
Researchers have found that a plasma exchange process can act as a molecular reset button for old blood, improving the health of ageing mice.
From inception to conclusion: how digitalisation is impacting drug development
Phoebe Chubb explores how digitalisation is shaking up the world of drug discovery and development by increasing productivity and reducing human error.
The coronavirus: seasonality and host-specific action of a “sexy” killer
Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
Unlocking the power of machine learning for small molecule drug discovery
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
Targeting SARM1 to protect vision across retinal degenerative diseases
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
3D bioprinting COVID-19 lung models for drug development
Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
Why are women underrepresented in COVID-19 research authorship?
An analysis of papers relating to COVID-19 has found that female researchers make up a third of authors. Here, the potential reasons behind this figure are explored and a possible solution to encourage equality.
What immuno-oncology research can tell us about COVID-19
Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
Antibody library screening: high throughput strategies
As the number of antibody discovery platforms and formats expands, various characteristics must be rigorously screened for and taken into consideration when deciding which hits to progress to successful development. The earlier in the antibody discovery pathway the assessment is carried out, the greater the hit enrichment and selection will…
TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19
Arsalan Azimi explains why inhibiting TMPRSS2 with clinically proven protease blockers could work as a therapeutic strategy against COVID-19.
The effect of temperature and humidity on the number of cases and deaths of COVID-19 all over the world
Sarah Ahmed explores how environmental factors may be causing the disparity in numbers of cases between different countries.
Application of organoid technology for retinal disease modelling and drug discovery
The loss of retinal light-sensing photoreceptor cells is a leading cause of blindness and the number of individuals affected by retinal degenerative diseases is increasing with an ageing population. Currently, there are no treatments for these diseases and progress in finding new treatments is slow. This article explores the potential…
Using big data approaches to develop cell therapies
An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further…